
    
      This is a double-arm, single-center study. This study is indicated for relapsed and/or
      refractory B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin's lymphoma and multiple
      myeloma, the selections of dose levels and the number of subjects are based on clinical
      trials of similar foreign products. 120 patients will be enrolled for this trial. Primary
      objective is to explore the safety.
    
  